Minimizing Morbidity of Cardiopulmonary Bypass, Valve, and Aortic Surgery
The William K. Edmark Professor of Cardiovascular Surgery Despite advances in traditional techniques,coronary artery bypass graft cardiac surgery is associated with a mortality rate of 1−4%, as well as a 1−4% incidence of perioperative myocardial infarction (MI) and stroke, or changes in neurological and neuropsychological function. Morbidity is even higher in complex valve and aortic pathologies. Our research efforts are divided into two categories: 1) limit morbidity of cardiopulmonary bypass (CPB), cell salvage and transfusion; and 2) develop alternative therapies for complex aortic and valvular pathologies that do not require CPB.
Extracorporeal Research
mcmullanD. Michael McMullan, MD Professor Clinical Director, ECMO Services, Seattle Children’s HospitalChildren and adults with severe, life-threatening cardiopulmonary failure represent some of the most challenging patients in modern medicine. When standard therapeutic interventions are inadequate to support these patients, extracorporeal membrane oxygenation (ECMO) may be used to provide temporary hemodynamic and respiratory stabilization. ECMO involves the use of a specialized external blood pump and oxygenator to either replace or partially support the function of a patient’s heart and lungs. Since its introduction three decades ago, over 27,000 patients have been supported by ECMO, with over 1,700 supported in 2009 alone.Complete Research Report >>
Cytokines and Chemokines in Direct Ischemia Reperfusion Injury of Lung and Cardiothoracic Transplant Rejection
The UW Distinguished Endowed Professor in Lung Transplant Research Lung transplantation, which was introduced into clinical practice nearly twenty years ago, has become an option for selected patients with end stage lung disease. Refi nements in patient selection, perioperative care and immunosuppression have resulted in improved three-year survival rates of 70%. Despite these improved outcomes, ischemia-reperfusion, an unavoidable consequence of transplantation, compromises the early and late function of the transplanted lung. Twenty-fi ve percent of transplant recipients experience some degree of reperfusion injury. In addition to acute morbidity, this acute inflammatory injury may compromise the long-term viability of the graft.